Buyout is about more than just acquiring a particular process or technology, it is also about acquiring the talent that fuels the innovation and passion in the co. Many mnta scientists would likely be turned off by the culture change of a big pharma buyout ... nvs has to think long and hard about the holistic implication of a buyout. Monetization may be a good compromise and ensures a good relationship with the co. I think most mnta shareholders would also welcome this compromise since it ensures long term ORGANIC growth.
Market Data 
Markets 
AI
